Literature DB >> 33819424

Optotheranostic Nanosystem with Phone Visual Diagnosis and Optogenetic Microbial Therapy for Ulcerative Colitis At-Home Care.

Meihui Cui1, Gaoju Pang1, Tao Zhang2, Tao Sun3,4, Lili Zhang1, Ruru Kang1, Xin Xue1, Huizhuo Pan1, Chun Yang1, Xinyu Zhang1, Jin Chang1, Jing Liu1, Shufang Zhang2, Hanjie Wang1.   

Abstract

Ulcerative colitis (UC) is a relapsing disorder characterized by chronic inflammation of the intestinal tract. However, the home care of UC based on remote monitoring, due to the operational complexity and time-consuming procedure, restrain its widespread applications. Here we constructed an optotheranostic nanosystem for self-diagnosis and long-acting mitigations of UC at home. The system included two major modules: (i) A disease prescreening module mediated by smartphone optical sensing. (ii) Disease real-time intervention module mediated by an optogenetic engineered bacteria system. Recombinant Escherichia coli Nissle 1917 (EcN) secreted interleukin-10 (IL-10) could downregulate inflammatory cascades and matrix metalloproteinases; it is a candidate for use in the therapeutic intervention of UC. The results showed that the Detector was able to analyze, report, and share the detection results in less than 1 min, and the limit of detection was 15 ng·mL-1. Besides, the IL-10-secreting EcN treatment suppressed the intestinal inflammatory response in UC mice and protected the intestinal mucosa against injury. The optotheranostic nanosystems enabled solutions to diagnose and treat disease at home, which promotes a mobile health service development.

Entities:  

Keywords:  engineering bacteria; gut; optogenetics; optotheranostic nanosystem; smartphone; ulcerative colitis

Year:  2021        PMID: 33819424     DOI: 10.1021/acsnano.1c00135

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  8 in total

1.  Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery.

Authors:  Jun Zhou; Maoyi Li; Qiufang Chen; Xinjie Li; Linfu Chen; Ziliang Dong; Wenjun Zhu; Yang Yang; Zhuang Liu; Qian Chen
Journal:  Nat Commun       Date:  2022-06-14       Impact factor: 17.694

Review 2.  Engineered probiotics.

Authors:  Junheng Ma; Yuhong Lyu; Xin Liu; Xu Jia; Fangyun Cui; Xiaoheng Wu; Shanshan Deng; Changwu Yue
Journal:  Microb Cell Fact       Date:  2022-04-27       Impact factor: 6.352

Review 3.  Next-Generation Probiotics for Inflammatory Bowel Disease.

Authors:  Marcella Pesce; Luisa Seguella; Alessandro Del Re; Jie Lu; Irene Palenca; Chiara Corpetti; Sara Rurgo; Walter Sanseverino; Giovanni Sarnelli; Giuseppe Esposito
Journal:  Int J Mol Sci       Date:  2022-05-13       Impact factor: 6.208

4.  All-in-one theranostic nano-platform based on polymer nanoparticles for BRET/FRET-initiated bioluminescence imaging and synergistically anti-inflammatory therapy for ulcerative colitis.

Authors:  Xiangji Yan; Chunhua Yang; Mei Yang; Yana Ma; Yuanyuan Zhang; Yujie Zhang; Cui Liu; Qiuran Xu; Kangsheng Tu; Mingzhen Zhang
Journal:  J Nanobiotechnology       Date:  2022-03-02       Impact factor: 10.435

Review 5.  Optogenetics in bacteria - applications and opportunities.

Authors:  Florian Lindner; Andreas Diepold
Journal:  FEMS Microbiol Rev       Date:  2022-03-03       Impact factor: 16.408

Review 6.  Achieving spatially precise diagnosis and therapy in the mammalian gut using synthetic microbial gene circuits.

Authors:  Clare M Robinson; Nina E Short; David T Riglar
Journal:  Front Bioeng Biotechnol       Date:  2022-09-02

Review 7.  The multifaceted roles of common gut microbiota in immune checkpoint inhibitor-mediated colitis: From mechanism to clinical application.

Authors:  Xu Han; Dan Zang; Dan Liu; Jun Chen
Journal:  Front Immunol       Date:  2022-09-14       Impact factor: 8.786

Review 8.  Native and Engineered Probiotics: Promising Agents against Related Systemic and Intestinal Diseases.

Authors:  Haokun Shen; Zitong Zhao; Zengjue Zhao; Yuyi Chen; Linghua Zhang
Journal:  Int J Mol Sci       Date:  2022-01-06       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.